3-deazaneplanocin has been researched along with tretinoin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benoit, YD; Gudas, LJ; Laursen, KB; Lipkin, SM; Witherspoon, MS | 1 |
| Borutinskaitė, V; Jasnauskaitė, M; Navakauskienė, R; Stirblytė, I; Valiulienė, G | 1 |
2 other study(ies) available for 3-deazaneplanocin and tretinoin
| Article | Year |
|---|---|
Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
Topics: Adenosine; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Epigenomics; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; HT29 Cells; Humans; MCF-7 Cells; Neoplasm Proteins; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Tretinoin | 2013 |
Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
Topics: Acetylation; Adenosine; Apoptosis; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Drug Interactions; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; HL-60 Cells; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Sulfonamides; Transcription Factors; Tretinoin | 2017 |